Quarterly report pursuant to Section 13 or 15(d)

CONDENSED STATEMENTS OF OPERATIONS

v3.8.0.1
CONDENSED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Operating expenses:        
Research and development $ 2,188 $ 569 $ 5,388 $ 1,718
Research and development - licenses acquired 300 0 2,375 0
General and administrative 4,596 1,101 8,293 1,814
Total operating expenses 7,084 1,670 16,056 3,532
Loss from operations (7,084) (1,670) (16,056) (3,532)
Other income (expense)        
Interest income 144 0 369 0
Interest expense - related party 0 (46) 0 (220)
Interest expense 0 (156) 0 (156)
Change in fair value of derivative liabilities 0 2 0 2
Total other income (expense) 144 (200) 369 (374)
Net Loss $ (6,940) $ (1,870) $ (15,687) $ (3,906)
Net loss per common share outstanding, basic and diluted $ (0.27) $ (0.19) $ (0.63) $ (0.39)
Weighted average number of common shares outstanding, basic and diluted 26,186,924 10,089,269 24,936,626 10,130,338